# reload+after+2024-01-23 10:27:17.758529
address1§215 Church Street
city§New Haven
state§CT
zip§06510
country§United States
phone§203 404 0410
website§https://www.biohaven.com
industry§Biotechnology
industryKey§biotechnology
industryDisp§Biotechnology
sector§Healthcare
sectorKey§healthcare
sectorDisp§Healthcare
longBusinessSummary§Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
fullTimeEmployees§202
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Vladimir  Coric M.D.', 'age': 52, 'title': 'Chairman & CEO', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 1850705, 'exercisedValue': 0, 'unexercisedValue': 1634000}, {'maxAge': 1, 'name': 'Mr. Matthew  Buten', 'age': 62, 'title': 'Chief Financial Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 939453, 'exercisedValue': 0, 'unexercisedValue': 516000}, {'maxAge': 1, 'name': 'Dr. Bruce D. Car DACVP, Ph.D.', 'age': 61, 'title': 'Chief Scientific Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 646887, 'exercisedValue': 0, 'unexercisedValue': 516000}, {'maxAge': 1, 'name': 'Ms. Deb  Young', 'title': 'Director of Regulatory Affairs & Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. George C. Clark', 'age': 39, 'title': 'VP & Chief Accounting Officer', 'yearBorn': 1984, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jennifer  Porcelli', 'title': 'Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Warren  Volles J.D.', 'title': 'General Counsel & Chief Legal Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Clifford  Bechtold M.S.', 'title': 'Chief Compliance Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kimberly  Gentile', 'age': 57, 'title': 'Senior Vice President of Clinical Operations', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John  Tilton', 'age': 55, 'title': 'Chief Commercial Officer of Rare Diseases', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§4
boardRisk§6
compensationRisk§8
shareHolderRightsRisk§3
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
currency§USD
dateShortInterest§1702598400
forwardEps§-5.34
exchange§NYQ
quoteType§EQUITY
shortName§Biohaven Ltd.
longName§Biohaven Ltd.
firstTradeDateEpochUtc§1663939800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§2bb7b4da-cd98-31f5-9833-032448a765e9
messageBoardId§finmb_1796230042
gmtOffSetMilliseconds§-18000000
targetHighPrice§58.0
targetLowPrice§31.0
targetMeanPrice§38.75
targetMedianPrice§35.5
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§8
quickRatio§4.109
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
